Answers are grounded in this paper and cite their sources.
Pilot study shows correlation between novel autoantibodies and dermatologic events in patients with advanced urothelial cancer, suggesting they may serve as biomarkers for toxicity response.
Enfortumab vedotin (EV) plus pembrolizumab is the first-line treatment for patients with advanced urothelial cancer (aUC). No biomarker for EV toxicity or response has been prospectively validated. EV-related dermatologic events (EVDEs) are common and correlate with improved outcomes in retrospective studies. Immune checkpoint inhibitor (ICI) related toxicity also correlates with improved outcomes, and the presence of autoantibodies correlates with improved responses. We hypothesized that EV unmasks preexisting subclinical autoimmune responses leading to EVDEs in the setting of EV or EV/P. Our goal was to determine whether novel autoantibodies, if detected, correlate with EVDEs. We screened for novel autoantibodies using an immunoprecipitation-based approach in a pilot retrospective cohort (A) and a prospective longitudinal cohort (B) of patients with aUC treated with EV- or EV/P and experienced EVDEs. Incidence of EVDEs, radiographic response, progression free and overall survival were compared between patients with and without autoantibodies. 2/6 cohort A patients had pre-treatment autoantibodies (Rho Associated Coiled-Coil Containing Protein Kinase 2 (1 patient), Target Of Myb1 Like 1 Membrane Trafficking Protein (1 patient)). Pre-treatment autoantibodies were also identified in 6/23 cohort B patients (Mitochondrial complex 3 – M2 Antigen (4 patients), NMD3 ribosome export adaptor (2 patients), and Carnitine palmitoyltransferase (one patient)). 6/6 (100%) cohort B antibody-positive patients developed EVDEs during treatment. To our knowledge, this is the first study correlating EVDEs with novel pre-treatment autoantibodies in patients with mUC. Further studies are needed to confirm that they are biomarkers of EV-related skin toxicity and/or response.
No takes yet. Share an insight, caveat, or question.
Vlachou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: